红日药业：注射用胸腺法新一致性评价处于审评中

Core Viewpoint - The company is facing scrutiny regarding its ability to pass the consistency evaluation for its injectable thymosin alpha-1, with concerns raised about its research and development capabilities in a competitive pharmaceutical environment [1] Group 1: Company Response - The company acknowledged the investor's concerns and clarified that the delay in the consistency evaluation process is a normal part of the review procedure by the National Medical Products Administration [1] - The company emphasized its commitment to comply with legal and regulatory requirements for information disclosure [1]